Apotea AB (publ) (STU:V30) EPS without NRI: €0.21 (TTM As of Mar. 2026)


STU:V30 Apotea AB (publ) STU:V30
18 GF Score
Price €6.77
! 1 Warning Sign
View Full Analysis

What is Apotea AB (publ) EPS without NRI?

Apotea AB (publ) STU:V30 +0.74% 18 EPS without NRI is €0.21 as of Mar. 2026. GuruFocus rates STU:V30 with a GF Score™ of 18/100. The stock has 1 warning sign investors should review. Among 513 Healthcare Providers & Services companies, Apotea AB (publ) ranks better than 97.08% on this metric.

Apotea AB (publ)'s earnings per share without non-recurring items for the three months ended in Mar. 2026 was €0.07. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was €0.21.

During the past 12 months, Apotea AB (publ)'s average earnings per share (NRI) Growth Rate was -0.90% per year. During the past 3 years, the average earnings per share (NRI) Growth Rate was 96.50% per year. During the past 10 years, the average earnings per share (NRI) Growth Rate was 0.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for Apotea AB (publ)'s EPS without NRI or its related term are showing as below:

STU:V30' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 27.5   Med: 62   Max: 96.5
Current: 96.5

During the past 5 years, Apotea AB (publ)'s highest 3-Year average Earnings Per Share (NRI) Growth Rate was 96.50% per year. The lowest was 27.50% per year. And the median was 62.00% per year.

STU:V30's 3-Year EPS without NRI Growth Rate is ranked better than
97.08% of 513 companies
in the Healthcare Providers & Services industry
Industry Median: 11.6 vs STU:V30: 96.50

Apotea AB (publ)'s EPS (Diluted) for the three months ended in Mar. 2026 was €0.07. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was €0.21.

Apotea AB (publ)'s EPS (Basic) for the three months ended in Mar. 2026 was €0.07. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 was €0.21.


Apotea AB (publ)  (STU:V30) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Apotea AB (publ) EPS without NRI Related Terms


Apotea AB (publ) EPS without NRI Historical Data

* Premium members only.

The historical data trend for Apotea AB (publ)'s EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Apotea AB (publ) EPS without NRI Chart

Apotea AB (publ) Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
EPS without NRI
0.10 0.03 0.08 0.18 0.21

Apotea AB (publ) Quarterly Data
Dec21 Dec22 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EPS without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.06 0.06 0.06 0.01 0.07

Apotea AB (publ) EPS without NRI Competitor Comparison

For the Pharmaceutical Retailers subindustry, Apotea AB (publ)'s PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Apotea AB (publ) PE Ratio without NRI vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Apotea AB (publ)'s PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where Apotea AB (publ)'s PE Ratio without NRI falls into.


STU:V30
18GF Score
Apotea AB (publ) STU:V30
EPS without NRI is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Apotea AB (publ) EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.21

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS without NRI →
What does a EPS without NRI of €0.21 mean?
Apotea AB (publ) (STU:V30) has a EPS without NRI of €0.21 as of Mar. 2026. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Apotea AB (publ) and its competitors. According to the industry distribution chart, Apotea AB (publ) ranks #15 out of 513 companies in the Healthcare Providers & Services industry, placing it in the top 2.9%.
Is Apotea AB (publ)'s EPS without NRI too high?
Apotea AB (publ)'s current EPS without NRI is €0.21. Based on the distribution chart, Apotea AB (publ) ranks #15 out of 513 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, Apotea AB (publ) has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Apotea AB (publ)'s EPS without NRI compare to competitors?
According to the Healthcare Providers & Services industry distribution chart, Apotea AB (publ) ranks #15 out of 513 companies for EPS without NRI. This places Apotea AB (publ) in the top 3% of its industry — outperforming the majority of peers. The industry median EPS without NRI is 11.60. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS without NRI for a Healthcare Providers & Services company?
The median EPS without NRI among Healthcare Providers & Services companies is 11.60, based on 513 companies in the industry. Companies in the top quartile (top 25%) have a EPS without NRI significantly above this median, while those in the bottom quartile fall well below. However, EPS without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS without NRI mean?
A high EPS without NRI can signal that a stock is expensive relative to its fundamentals. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Apotea AB (publ) and its competitors. For the Healthcare Providers & Services industry, the median EPS without NRI is 11.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Apotea AB (publ)'s current EPS without NRI is €0.21. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Apotea AB (publ) stock overvalued right now?
Apotea AB (publ) (STU:V30) has a current EPS without NRI of €0.21. The current EPS without NRI is €0.21. Apotea AB (publ)'s overall GF Score™ is 18/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS without NRI calculated?
EPS without NRI is calculated from a company's financial statements. For Apotea AB (publ) (STU:V30), the current EPS without NRI is €0.21 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Apotea AB (publ) Business Description

Other Exchanges APOTEA:Sweden
Address Sveavagen 168, Stockholm, SWE, 11346
Apotea AB (publ) is engaged in the online pharmacy with fast deliveries, good prices and a large selection. Its vision is to be tomorrow's pharmacy by constantly facilitating and simplifying for the customer.
18GF Score

Get the complete analysis for STU:V30

EPS without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€6.77
Price